Metrics to compare | IMMUN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMMUNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.3x | −0.5x | −0.5x | |
PEG Ratio | −0.14 | 0.00 | 0.00 | |
Price/Book | 0.6x | 2.7x | 2.6x | |
Price / LTM Sales | - | 0.0x | 3.1x | |
Upside (Analyst Target) | 188.3% | 0.0% | 52.5% | |
Fair Value Upside | Unlock | 47.6% | 6.0% | Unlock |
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company’s lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.